PPARγ agonists seem to protect neurons not only following acute CNS injury including stroke, spinal cord injury and TBI after which massive inflammation plays a detrimental role, but also in neurodegenerative conditions including multiple sclerosis (Diab et al., 2002; Chaudhuri, 2013), AD (Combs et al., 2000) and PD (Kapadia et al., 2008). Here, PPARG is linked to Alzheimer disease.